The only market access meeting place you'll need to be at this year
It’s our mission to maximise patient access to great medicines – and to be rewarded for it. That mission is true whether you’re in market access, product development, clinical trials or if you’re a payer.
Here’s the new part. It’s also increasingly true whether you work in commercial, R&D or medical functions.
Market access has moved from a vertical unit into a way of life, a skillset that must be learned by every employee, a mantra that must echo through every corridor of your office.
Your job has changed radically. You are the earpiece to the payer, ensuring that their desires are at the forefront of every plan and every initiative.
At eyeforpharma’s 2017 flagship access and pricing summit, we’ll show you how to adopt a new and harmonious market access culture. From clinical to commercial, access is now your ultimate goal.
This year at Europe’s no.1 meeting place for market access, pricing, reimbursement & data professionals, delegates learn how to:
- Bridge the gap: ensure a fully access-oriented strategy from clinical to commercial
- Know your stakeholders: map your routes to market for seamless patient access
- Prove your value: use data and innovative risk-sharing agreements for the reimbursement your portfolio deserves
- Stay ahead of the market: expert updates on the future evolution of European health policy
VP, Health Economics, Market Access & Reimbursement
Johnson & Johnson
RVP, Head of Market Access
VP Market Access & Governmental Affairs
Global Pricing & Market Access Director
Executive Director HEOR
VP Global Pricing & Market Access
Prof. Dr. Bertram Haussler
Our Track-Record of Proven Success
Conferences promise a lot - we know. Below are a few takeaways from the last year's Summit highlighting the valuable insights the attendees took away …
call our sessions essential
said they will likely return again next year
rated the program very well run
What our Delegates are saying
"This was one of the most relevant and comprehensive conferences, which I have attended in recent years. The speakers and meeting chairs were well selected."- Karel Mechelse, Market Access Strategy Leader, Bayer
"Well worth investing in... a place to exchange views and perspectives"- Frederic de Reydet, Global Market Access Director, Novartis
"An excellent representation of key European decision makers"- Myriam Zylberman, Senior Director - EU Payer Strategy, Eli Lilly
"A fascinating meeting of diverse speakers who outlined numerous themes around the need to prove the validity and trustworthiness of RWE, versus RCTs, with an emphasis on â€śreal timeâ€ť versus â€śreal worldâ€ť. Thank you eyeforpharma!"- Nigel Hughes, Global Director Marketing/ Health Information Technology Strategy Leader, Janssen